1-3 of 3
phosphoinositide 3-kinase
Close
Sort by
Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Journal: Blood Advances
Blood Adv (2021) 5 (3): 913–925.
https://doi.org/10.1182/bloodadvances.2020003768
Published: 2021
Includes: Supplemental data
Journal Articles

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

Neeraj Jain, Satishkumar Singh, Georgios Laliotis, Amber Hart, Elizabeth Muhowski, Kristyna Kupcova, Tereza Chrbolkova, Tamer Khashab, Sayan Mullick Chowdhury, Anuvrat Sircar, Fazal Shirazi, Ram Kumar Singh, Lapo Alinari, Jiangjiang Zhu, Ondrej Havranek, Philip Tsichlis, Jennifer Woyach, Robert Baiocchi, Felipe Samaniego, Lalit Sehgal
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4382–4392.
https://doi.org/10.1182/bloodadvances.2020001685
Published: 2020
Includes: Supplemental data
Journal Articles

The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

Kamira Maharaj, John J. Powers, Alex Achille, Melanie Mediavilla-Varela, Wael Gamal, Karen L. Burger, Renee Fonseca, Kun Jiang, Hari P. Miskin, Dave Maryanski, Andrii Monastyrskyi, Derek R. Duckett, William R. Roush, John L. Cleveland, Eva Sahakian, Javier Pinilla-Ibarz
Journal: Blood Advances
Blood Adv (2020) 4 (13): 3072–3084.
https://doi.org/10.1182/bloodadvances.2020001800
Published: 2020
Includes: Supplemental data